{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Adjuvant Treatment Strategies Following Neoadjuvant Chemoimmunotherapy in Resectable NSCLC"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients were categorized into no-treatment (n=46), chemotherapy (ChT) (n=38), immunotherapy (IT) (n=33), chemoimmunotherapy (ChIT) (n=168), and upfront surgery with adjuvant immunotherapy (US+AIT) (n=32) groups."
      },
      "Participants": {
        "score": 2,
        "evidence": "317 patients with stage IB-IIIB NSCLC treated at Shandong Cancer Hospital from January 2019 to February 2024."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients were categorized into no-treatment (n=46), chemotherapy (ChT) (n=38), immunotherapy (IT) (n=33), chemoimmunotherapy (ChIT) (n=168), and upfront surgery with adjuvant immunotherapy (US+AIT) (n=32) groups."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate adjuvant treatment strategies following neoadjuvant chemoimmunotherapy (NCIT) in patients with resectable non-small cell lung cancer (NSCLC)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Event-free survival (EFS) and overall survival (OS) were primary outcomes, assessed over a median follow-up of 30.7 months."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "317 patients with stage IB-IIIB NSCLC treated at Shandong Cancer Hospital from January 2019 to February 2024."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Patients were categorized into no-treatment (n=46), chemotherapy (ChT) (n=38), immunotherapy (IT) (n=33), chemoimmunotherapy (ChIT) (n=168), and upfront surgery with adjuvant immunotherapy (US+AIT) (n=32) groups."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "IT and ChIT groups showed improved EFS compared to the no-treatment group."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not applicable."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 15,
    "max_score": 25
  },
  "model": "gpt-4o"
}